Identification of important interactions between subchondral bone ...

1482 S.H. Madsen et al. / Steroids 76 (2011) 1474–1482
[23] Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoiddependent
regulation of Wnt expression and its inhibitors in mature
osteoblastic cells. Calcif Tissue Int 2009;85(6):538–45.
[24] Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, et al. Transgenic
disruption of glucocorticoid signaling in mature osteoblasts and osteocytes
attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum
2009;60(7):1998–2007.
[25] Zalavras C, Shah S, Birnbaum MJ, Frenkel B. Role of apoptosis in glucocorticoidinduced
osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr
2003;13(2–4):221–35.
[26] Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the
femoral head: a new understanding of the mechanisms of action. J Steroid
Biochem Mol Biol 2009;114(3–5):121–8.
[27] Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P,
et al. Should subchondral bone turnover be targeted when treating
osteoarthritis? Osteoarthritis Cartilage 2008;16(6):638–46.
[28] Kwan TS, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral
bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin
Rheumatol 2010;24(1):51–70.
[29] Madsen SH, Goettrup AS, Thomsen G, Christensen ST, Schultz N, Henriksen K,
et al. Characterization of an ex vivo femoral head model assessed by markers
of bone and cartilage turnover. Cartilage 2011;2(3):265–78.
[30] Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard
BC. Cartilage degradation is fully reversible in the presence of aggrecanase but
not matrix metalloproteinase activity. Arthritis Res Ther 2008;10(3):R63.
[31] Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH,
et al. Characterization of osteoclasts derived from CD14 + monocytes isolated
from peripheral blood. J Bone Miner Metab 2007;25(1):36–45.
[32] Ghosh-Choudhury N, Windle JJ, Koop BA, Harris MA, Guerrero DL, Wozney JM,
et al. Immortalized murine osteoblasts derived from BMP 2-T-antigen
expressing transgenic mice. Endocrinology 1996;137(1):331–9.
[33] Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al.
Anabolic and catabolic function of chondrocyte ex vivo is reflected by the
metabolic processing of type II collagen. Osteoarthritis Cartilage
2007;15(3):335–42.
[34] Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K.
Osteoclasts secrete non-bone derived signals that induce bone formation.
Biochem Biophys Res Commun 2008;366(2):483–8.
[35] Jonsson KB, Frost A, Larsson R, Ljunghall S, Ljunggren O. A new fluorometric
assay for determination of osteoblastic proliferation: effects of glucocorticoids
and insulin-like growth factor-I. Calcif Tissue Int 1997;60(1):30–6.
[36] Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked
immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen
neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic
osteoarthritis. Clin Biochem 2011;44(5-6):423–9.
[37] Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA,
et al. MMP and non-MMP-mediated release of aggrecan and its fragments
from articular cartilage: a comparative study of three different aggrecan and
glycosaminoglycan assays. Osteoarthritis Cartilage 2007;15(2):212–21.
[38] Henriksen K, Gram J, Neutzsky-Wulff AV, Jensen VK, Dziegiel MH, Bollerslev J,
et al. Characterization of acid flux in osteoclasts from patients harboring a
G215R mutation in ClC-7. Biochem Biophys Res Commun 2009;378(4):804–9.
76
[39] Camplejohn KL, Allard SA. Limitations of safranin ‘O’ staining in proteoglycandepleted
cartilage demonstrated with monoclonal antibodies. Histochemistry
1988;89(2):185–8.
[40] Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol
2009;28(7):749–56.
[41] Skwara A, Peterlein CD, Tibesku CO, Rosenbaum D, Fuchs-Winkelmann S.
Changes of gait patterns and muscle activity after intraarticular treatment of
patients with osteoarthritis of the knee: a prospective, randomised,
doubleblind study. Knee 2009;16(6):466–72.
[42] Mansell JP, Collins C, Bailey AJ. Bone, not cartilage, should be the major focus in
osteoarthritis. Nat Clin Pract Rheumatol 2007;3(6):306–7.
[43] van der Kraan PM, Vitters EL, Postma NS, Verbunt J, Van den Berg WB.
Maintenance of the synthesis of large proteoglycans in anatomically intact
murine articular cartilage by steroids and insulin-like growth factor I. Ann
Rheum Dis 1993;52(10):734–41.
[44] Madsen SH, Sumer EU, Bay-Jensen AC, Sondergaard BC, Qvist P, Karsdal MA.
Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is
associated with different molecular characteristics of aggrecan and separated
in time ex vivo. Biomarkers 2010;15(3):266–76.
[45] Augustine AJ, Oleksyszyn J. Glucocorticosteroids inhibit degradation in bovine
cartilage explants stimulated with concomitant plasminogen and interleukin-
1 alpha. Inflamm Res 1997;46(2):60–4.
[46] Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al.
Glucocorticoids suppress bone formation by attenuating osteoblast
differentiation via the monomeric glucocorticoid receptor. Cell Metab
2010;11(6):517–31.
[47] Kalak R, Zhou H, Street J, Day RE, Modzelewski JR, Spies CM, et al. Endogenous
glucocorticoid signalling in osteoblasts is necessary to maintain normal bone
structure in mice. Bone 2009;45(1):61–7.
[48] Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent
parathyroid hormone administration counteracts the adverse effects of
glucocorticoids on osteoblast and osteocyte viability, bone formation, and
strength in mice. Endocrinology 2010;151(6):2641–9.
[49] Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local
communication on and within bone controls bone remodeling. Bone
2009;44(6):1026–33.
[50] Jevon M, Hirayama T, Brown MA, Wass JA, Sabokbar A, Ostelere S, et al.
Osteoclast formation from circulating precursors in osteoporosis. Scand J
Rheumatol 2003;32(2):95–100.
[51] Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y.
Dexamethasone enhances osteoclast formation synergistically with
transforming growth factor-beta by stimulating the priming of osteoclast
progenitors for differentiation into osteoclasts. J Biol Chem
2003;278(45):44667–74.
[52] Soe K, Delaisse JM. Glucocorticoids maintain human osteoclasts in the active
mode of their resorption cycle. J Bone Miner Res 2010 [Epub ahead of print].
Ref Type: Generic.